MT-3921

BIOLOGICAL3 trials

Sponsors

Tanabe Pharma America, Inc., Tanabe Pharma Corporation

Conditions

HTLV-1-Associated Myelopathy (HAM)Healthy Adult MalesSpinal Cord Injury

Phase 1

A Clinical Pharmacological Study of MT-3921 in Subjects With HTLV-1 Associated Myelopathy (HAM)

CompletedNCT05240612

Tanabe Pharma CorporationHTLV-1-Associated Myelopathy (HAM)

Start: 2022-05-02End: 2023-12-28Updated: 2024-01-29

A Clinical Pharmacology Study of MT-3921 in Healthy Adult Males

CompletedNCT05396235

Tanabe Pharma CorporationHealthy Adult Males

Start: 2022-08-03End: 2022-12-24Updated: 2023-01-18

Phase 2

Study to Assess the Efficacy and Safety of MT-3921 in Subjects With Acute Traumatic Cervical Spinal Cord Injury

CompletedNCT04683848

Tanabe Pharma America, Inc.Spinal Cord Injury

Start: 2021-08-27End: 2025-04-09Updated: 2025-12-16